Assessment of efficacy and safety of SARS-Cov-2 vaccination in patients with inflammatory Bowel Diseases and on anti-TNF alpha or combination treatment of biologics plus immunomodulators
Latest Information Update: 29 Jul 2022
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 29 Jul 2022 New trial record